18:14 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

AnaptysBio's asthma therapy improves eosinophil count and lung function in Phase IIa

AnaptysBio Inc. (NASDAQ:ANAB) reported interim data from a Phase IIa trial to treat severe eosinophilic asthma showing that etokimab (formerly ANB020) improved eosinophil count and lung function vs. placebo. A single 300 mg dose of...
18:13 , Sep 28, 2018 |  BC Week In Review  |  Financial News

AnaptysBio raises $208M following Phase IIa asthma readout

AnaptysBio Inc. (NASDAQ:ANAB) raised $207.8 million late Sept. 25 through the sale of 2.2 million shares at $94.46 in a follow-on underwritten by Credit Suisse, J.P. Morgan, Jefferies, Cantor, Guggenheim Securities and Wedbush PacGrow. The...
17:32 , Sep 26, 2018 |  BC Extra  |  Financial News

AnaptysBio raises $208M following Phase IIa asthma readout

AnaptysBio Inc. (NASDAQ:ANAB) raised $207.8 million late Tuesday through the sale of 2.2 million shares at $94.46 in a follow-on underwritten by Credit Suisse, J.P. Morgan, Jefferies, Cantor, Guggenheim Securities and Wedbush PacGrow. The financing...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
18:24 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

AnaptysBio reports Phase IIa data for peanut allergy candidate

AnaptysBio Inc. (NASDAQ:ANAB) reported interim data from a Phase IIa trial showing that six of 13 (46%) patients exhibiting moderate to severe peanut allergy symptoms during a baseline oral food challenge improved their peanut tolerance...
23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
18:01 , Oct 20, 2017 |  BC Week In Review  |  Financial News

AnaptysBio raises $205.5M in follow-on

AnaptysBio Inc. (NASDAQ:ANAB) raised $205.5 million through the sale of 3 million shares at $68.50 in a follow-on underwritten by Credit Suisse, Jefferies, Stifel, Wedbush, Baird and SunTrust. The price is a 3% discount to...
20:58 , Oct 13, 2017 |  BC Extra  |  Financial News

AnaptysBio raises $205.5M in follow-on

AnaptysBio Inc. (NASDAQ:ANAB) raised $205.5 million through the sale of 3 million shares at $68.50 in a follow-on underwritten by Credit Suisse, Jefferies, Stifel, Wedbush, Baird and SunTrust. The price is a 3% discount to...
19:47 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

AnaptysBio's ANB020 meets objective in Phase IIa for atopic dermatitis

AnaptysBio Inc. (NASDAQ:ANAB) said lead program ANB020, an antibody against IL-33, “achieved the trial protocol objective” in a Phase IIa trial to treat moderate to severe atopic dermatitis. The company said the trial had no...